Pelthos Therapeutics Inc. (PTHS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $6.84
- As of
Kresmion compiles this page from PTHS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Pelthos Therapeutics Inc. (PTHS): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-12.
See the full PTHS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PTHS on one page. Preview it with sample data, then open it live with a free account.
Preview the PTHS dossierActive events for PTHS
- highActivist stake
Activist 13D filing, dividend
- medium13F: new position
CITADEL ADVISORS LLC new position in PTHS
- mediumEarnings below estimates
Q2-2026: Missed consensus by 113.0%, EPS $-6.62 vs $-3.1081 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 15.7% - EPS $-5.38 vs $-6.3852 estimate
- mediumEarnings below estimates
Q3-2025: Missed consensus by 1108.4% - EPS $-5.3 vs $-0.4386 estimate
FREE, NO ACCOUNT
Every event on PTHS, as it fires
You are seeing 5 of 7 events recorded on PTHS since 2026-05-27.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, PTHS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on PTHS
- PTHS share buybacks Cash paid for repurchases, shares bought and program authorizations, from SEC filings.
- PTHS insider trading clusters Three or more insiders filing the same direction within 30 days, from SEC Form 4.
- PTHS against its peers Growth, margins and valuation beside the industry median, from annual SEC filings.
PTHS against its peers
PTHS's return on equity of -111.4% ranks in the 58th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-07-31.
| Metric | PTHS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 16.8M USD | 25000 USD | 94 | 8 |
| Gross margin | 76.3% | n/a | n/a | 1 |
| Operating margin | -193.1% | n/a | n/a | 4 |
| Net margin | -257.9% | n/a | n/a | 4 |
| Return on equity | -111.4% | -124.0% | 58 | 17 |
| 1 year | -75.3% | -53.3% | 23 | 19 |
Peers (21): RNTX, BCTX, KLRS, EXOZ, INMB, SER, NNVC, VERU, HYPD, ALDX, TIL, ANVS, BMEA, LONA, LITS, QNCX, OSTX, GRCE, CRBU, BRNS, PMN. Left out: ZIVO (period gap), CLCS (period gap), RLFTY (no annual filing), SEOVF (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-07-31. Every figure is one full fiscal year read from one annual filing (PTHS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in PTHS on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on PTHS in the last 180 days.
Upstream: SEC EDGAR filings for PTHS
Kresmion, "Pelthos Therapeutics Inc. (PTHS) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/PTHS. Upstream data: SEC EDGAR filings for PTHS.
Link to this data (HTML):
<a href="https://kresmion.com/research/PTHS">Pelthos Therapeutics Inc. (PTHS) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow PTHS on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to PTHS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.